Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges
The pharmaceutical business model is naturally vulnerable to such competitive price declines, combining as it does high upfront investment costs and low production costs to make each dose
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, GSK, Regeneron Pharmaceuticals Inc., Pfizer Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, ZEALAND PHARMA, Hanmi Pharm
The underlying rationale is somatopause the normal, age-related decline in GH secretion which is a physiologic process, not a disease
Loreto, A., Antoniou, C., Merlini, E., Gilley, J
US$ 21.34
US$ 26.83
US$ 20.74
